Asset profile
Manfidokimab
Monoclonal antibody
Evidence outlook · registrational
Atopic Dermatitis: registrational readout pending
Entered Phase 3 on weak signal mid-stage evidence. Registrational readout expected around 2027-07-10.
NCT06700499: The study was a 450-participant, open-label, single-arm trial with no placebo or active comparator, so it cannot directly determine efficacy or comparative safety. Its primary safety endpoint has no posted results, and the study design does not provide controlled evidence of benefit.
Also in development:Asthma · Phase 2
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
126 competitors in this universe: 6 direct rivals (same mechanism and indication), 0 same-class, 120 same-indication; 49 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Manfidokimab: this drug | Phase 3 | Monoclonal antibody | IL-4R-alpha | ||
| Dupilumab (Dupixent) | Approved | Monoclonal antibody | IL-4R-alpha | ||
| GS101 | Phase 3 | Monoclonal antibody | IL-4R-alpha | ||
| QL2108 | Phase 3 | Monoclonal antibody | IL-4R-alpha | ||
| Rademikibart | Phase 3 | Monoclonal antibody | IL-4R-alpha | ||
| Stapokibart | Phase 3 | Monoclonal antibody | IL-4R-alpha | ||
| CKD-706 | Phase 1 | Monoclonal antibody | IL-4R-alpha | ||
| Abrocitinib (Cibinqo) | Approved | Small molecule | JAK1 | ||
| Albuterol (Armstrong Albuterol HFA) | Approved | Small molecule | Beta-2 adrenergic receptor | ||
| Albuterol / Budesonide (Airsupra) | Approved | Combination | Beta-2 adrenergic receptor, Glucocorticoid receptor, Glucocorticoid receptor / Beta-2 adrenergic receptor | ||
| Albuterol HFA (Armstrong's) | Approved | Small molecule | Beta-2 adrenergic receptor | ||
| Albuterol HFA (Proventil HFA) | Approved | Small molecule | Beta-2 adrenergic receptor | ||
| Albuterol Sulfate (Armstrong) | Approved | Small molecule | Beta-2 adrenergic receptor | ||
| Albuterol Sulfate (Provenetil-HFA) | Approved | Small molecule | Beta-2 adrenergic receptor | ||
| Aminophylline | Approved | Small molecule | Phosphodiesterase (multi-subtype) | ||
| Baricitinib (Olumiant) | Approved | Small molecule | JAK, JAK1/2 |
…and 111 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (1)
July 2027 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.